Please login to the form below

Not currently logged in
Email:
Password:

Gavin Giovannoni

This page shows the latest Gavin Giovannoni news and features for those working in and with pharma, biotech and healthcare.

Merck Serono's MS drug approved in Russia

We expect other regulatory approvals in the near future.". Gavin Giovannoni of the UK's Blizard Institute of Cell and Molecular Science and principal investigator of CLARITY, said the approval will

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The role of brain health in treating MS

    Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health, the ... Rather than treating and reducing relapses, top

  • Blue Latitude Health Blue Latitude Health

    Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health, the

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...